All News

The updated recommendations include CGRP inhibitors as a first-line treatment option for chronic and episodic migraine prevention.

Advanced cell therapies are now saving the lives of people whose blood cancer would previously have been incurable. While the UK was quick to recognize the potential of these innovative therapies, patient access to these therapies may change without continued investment in the UK's cell therapy infrastructure.

Imuldosa has received approval for all indications of its reference product, including ulcerative colitis, psoriatic arthritis, and Crohn disease.

Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.

Although respondents identified some exciting areas of growth, challenges remain, including the complex insurance system and ensuring patient medication adherence.

Two MUSC pharmacy technicians discuss how techs are pivotal in pharmacy, whether in the community or clinical setting, and how it is important to maintain high standard of care in a changing environment.

Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.

Investigators state that health care providers should consider the potential use of 2 doses to increase the effectiveness against influenza B.

Legislative efforts in the states and Washington, DC, have made progress, but there is still a way to go.

Simply stating a team member good job, whether it be within a group or in a 1-on-1 setting, 2 MUSC pharmacy technicians emphasize that recognition and encouragement go a long way.

Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.

The FDA faces a multitude of challenges in regulating artificial intelligence (AI) and machine learning (ML) medical devices.

Ilianette Miranda, RPh discusses her career-long efforts to integrate pharmacists into the health care system in Puerto Rico.

Behind The Script is a photo submission campaign designed to feature real pharmacists with candid, HIPAA-compliant photos to celebrate American Pharmacist Month.

In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.

The president and CEO of Employers' Forum of Indiana says the pharmacists must be involved and engaged with employers to improve outcomes in health care.

Pharmacists and the pharmacies they support are in a strong position to increase vaccination rates and address any questions related to vaccine hesitancy.

Employers can support technicians by investing in certification opportunities.

The authors of these peer -reviewed papers collectively emphasize the evolving landscape of oncology treatment.

Criticism and inquiry are coming from all directions. Will investors earn more by holding on to the past or transitioning toward the future?

The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.

Artificial intelligence (AI) is transforming drug development by automating routine tasks, enhancing clinical trials, and expediting drug discovery, ultimately leading to more personalized treatments.

Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.

This Women Pharmacists Day, Jolynn Sessions, PharmD, BCOP, FHOPA, discussed the crucial role of women in pharmacy.

High-resolution scans can provide a picture of a patient’s brain that typical MRIs cannot, allowing for more detailed insights into the neurological effects of COVID-19.

Terry Keys highlights the role of language and terminology as barriers for patients receiving cancer care.

The trial met its primary endpoint of event-free survival, furthering treatment options for resected, locally advanced head and neck squamous cell carcinoma.

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.